Studie - ZIOPHARM Oncology, Inc. – Product Pipeline Review – Q2 2011

ZIOPHARM Oncology, Inc. — Product Pipeline Review — Q2 2011

Summary

Global Market Direct’s pharmaceuticals report, 'ZIOPHARM Oncology, Inc. - Product Pipeline Review - Q2 2011” provides data on the ZIOPHARM Oncology, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, ZIOPHARM Oncology, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from ZIOPHARM Oncology, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- ZIOPHARM Oncology, Inc. - Brief ZIOPHARM Oncology, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ZIOPHARM Oncology, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ZIOPHARM Oncology, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ZIOPHARM Oncology, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate ZIOPHARM Oncology, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of ZIOPHARM Oncology, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ZIOPHARM Oncology, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ZIOPHARM Oncology, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ZIOPHARM Oncology, Inc. and identify potential opportunities in those areas.

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

ZIOPHARM Oncology, Inc. Snapshot 6

ZIOPHARM Oncology, Inc. Overview 6

Key Information 6

Key Facts 6

ZIOPHARM Oncology, Inc. — Research and Development Overview 7

Key Therapeutic Areas 7

ZIOPHARM Oncology, Inc. — Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products — Monotherapy 11

Pipeline Products — Combination Treatment Modalities 12

ZIOPHARM Oncology, Inc. — Pipeline Products Glance 13

ZIOPHARM Oncology, Inc. — Late Stage Pipeline 13

Phase III Products/Combination Treatment Modalities 13

ZIOPHARM Oncology, Inc. Clinical Stage Pipeline Products 14

Phase II Products/Combination Treatment Modalities 14

Phase I Products/Combination Treatment Modalities 15

ZIOPHARM Oncology, Inc.—Early Stage Pipeline Products 16

Pre-Clinical Products/Combination Treatment Modalities 16

ZIOPHARM Oncology, Inc. — Drug Profiles 17

Zymafos + Doxorubicin 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

Zinapar 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

Zybulin 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Zymafos 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Zymafos + Adriamycin 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Darinaparsin + CHOP 24

Product Description 24

Mechanism of Action 24

R&D Progress 25

Zinapar 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Zybulin + Erlotinib 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Zymafos + Doxorubicin 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Zymafos + Etoposide + Carboplatin 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Zinapar 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

ZIO-202 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

ZIO-203 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Zymafos Oral 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

ZIOPHARM Oncology, Inc. — Pipeline Analysis 37

ZIOPHARM Oncology, Inc. — Pipeline Products by Therapeutic Class 37

ZIOPHARM Oncology, Inc. - Pipeline Products By Target 39

ZIOPHARM Oncology, Inc. — Pipeline Products by Route of Administration 40

ZIOPHARM Oncology, Inc. — Pipeline Products by Molecule Type 41

ZIOPHARM Oncology, Inc. — Recent Pipeline Updates 42

ZIOPHARM Oncology, Inc. - Dormant Projects 43

ZIOPHARM Oncology, Inc. — Locations And Subsidiaries 44

Head Office 44

Other Locations & Subsidiaries 44

Financial Deals Landscape 45

ZIOPHARM Oncology, Inc., Deals Volume Summary, 2004 to YTD 2011 45

ZIOPHARM Oncology, Inc., Deals Summary By Region, 2004 to YTD 2011 46

ZIOPHARM Oncology, Inc., Deals Summary, 2004 to YTD 2011 47

ZIOPHARM Oncology, Inc. Detailed Deal Summary 48

Venture Financing 48

ZIOPHARM Raises $18 Million In Venture Financing 48

Equity Offering 49

ZIOPHARM Oncology Completes Public Offering For $48 Million 49

ZIOPHARM Oncology Completes Private Placement Of $5 Million 51

ZIOPHARM Enters Into Co-Development Agreement With Southern Research Institute 53

Licensing Agreements 54

ZIOPHARM Enters Into Licensing Agreement With DEKK-TEC 54

ZIOPHARM Enters Into Licensing Agreement With M. D. Anderson Cancer Center 55

Appendix 56

Methodology 56

Coverage 56

Secondary Research 56

Primary Research 56

Expert Panel Validation 57

Contact Us 57

Disclaimer 57



List of Tables

ZIOPHARM Oncology, Inc. — Pipeline by Therapy Area and Indication, 2011 8

ZIOPHARM Oncology, Inc. — Pipeline by Stage of Development, 2011 10

ZIOPHARM Oncology, Inc. — Monotherapy Products in Pipeline, 2011 11

ZIOPHARM Oncology, Inc. — Combination Treatment Modalities in Pipeline, 2011 12

ZIOPHARM Oncology, Inc. — Phase III, 2011 13

ZIOPHARM Oncology, Inc. - Phase II, 2011 14

ZIOPHARM Oncology, Inc. - Phase I, 2011 15

ZIOPHARM Oncology, Inc. - Pipeline By Therapeutic Class, 2011 38

ZIOPHARM Oncology, Inc. - Pipeline By Target, 2011 39

ZIOPHARM Oncology, Inc. — Pipeline By Route of Administration, 2011 40

ZIOPHARM Oncology, Inc. — Pipeline By Molecule Type, 2011 41

ZIOPHARM Oncology, Inc. — Recent Pipeline Updates, 2011 42

ZIOPHARM Oncology, Inc. - Dormant Developmental Projects, 2010 43

ZIOPHARM Oncology, Inc., Other Locations 44

ZIOPHARM Oncology, Inc., Deals Summary, 2004 to YTD 2011 45

ZIOPHARM Oncology, Inc., Deals Summary by Region, 2004 to YTD 2011 46

ZIOPHARM Oncology, Inc., Deals Summary, 2004 to YTD 2011 47



List of Figures

ZIOPHARM Oncology, Inc. — Pipeline by Therapy Area and Indication, 2011 8

ZIOPHARM Oncology, Inc. — Pipeline by Stage of Development, 2011 10

ZIOPHARM Oncology, Inc. — Monotherapy Products in Pipeline, 2011 11

ZIOPHARM Oncology, Inc. — Combination Treatment Modalities in Pipeline, 2011 12

ZIOPHARM Oncology, Inc. — Pipeline By Therapeutic Class, 2011 37

ZIOPHARM Oncology, Inc. - Pipeline By Target, 2011 39

ZIOPHARM Oncology, Inc. — Pipeline By Route of Administration, 2011 40

ZIOPHARM Oncology, Inc. — Pipeline By Molecule Type, 2011 41

• Consumer Health in Canada
• Consumer Health in Hong Kong, China
• Consumer Health in Turkey
• ICT Spend Predictions in Large Brazilian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Large Canadian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Large French Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Large German Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Large Mexican Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Large UK Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Large US Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized Brazilian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized Canadian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized French Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized German Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized Mexican Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized UK Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized US Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Small Brazilian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Small Canadian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Small French Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013